Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)

Home > Drug Product Listings > Pomalidomide > Printer-friendly PDF

Pomalidomide

Trade Name: Pomalyst Manufacturer/Distributor: Celgene Canada www.celgenecanada.net Classification: Antineoplastic agent; immunmodulator ATC Class: L04AX - Other immunosuppressants Status: active Notice of Compliance (yyyy/mm/dd): 2014/01/20 Date Marketed in Canada (yyyy/mm/dd): 2014/02/24 Presentation: Capsule: 1 mg. DIN: 02419580 Capsule: 2 mg. DIN: 02419599 Capsule: 3 mg. DIN: 02419602 Capsule: 4 mg. DIN: 02419610 Comments: Pomalidomide is indicated for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen. POMALYST? is only available through a controlled distribution program called RevAid®. Under this program, only prescribers and pharmacists registered with the program are able to prescribe and dispense the product. In addition, POMALYST? can only be dispensed to patients who are registered and meet all the conditions of the RevAid® program. Keywords: pomalidomide multiple myeloma Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: ? Search Terms:

Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Common Date Marketed in Generic Name Trade Classification Canada Name(s) (yyyy/mm/dd) Moroctocog alfa Xyntha Hemostatic agent 2009/01/23 Naloxegol Movantik Miscellaneous GI drug 2015/08/27 Naltrexone + bupropion Contrave Anorexigenic agents 2018/02/13 Naproxen + Vimovo NSAID + PPI 2011/01/14 Esomeprazole Beta-blocker, Nebivolol Bystolic 2013/04 cardioselective Niraparib Zejula Antineoplastic agent 2020/01/09 Norethindrone acetate + estrogen-progesterone femHRT 2012/10/09 ethinyl estradiol combination Norgestrel + ethinyl Ovral Oral contraceptive estradiol Ofatumumab Arzerra Antineoplastic agent 2012/03/09 Ofatumumab Kesimpta Immunomudulator 2021/04/08 Olmesartan Olmetec Antihypertensive agent 2009/02 Olmesartan + Olmetec Plus Antihypertensive agent 2009/02 hydrochlorothiazide Olopatadine Pataday Anti-allergy agent 2011/04/14 Cellular and gene Onasemnogene Zolgensma 2021/02/04 therapy Ondissolve Ondansetron Antiemetic 2013/04 ODF Anticholinergic / Oxybutynin Gelnique 2012/03/05 Antispasmodic Oxybutynin Uromax Urinary Antispasmodic Oxycodone OxyContin Narcotic 2012/02/29 Oxycodone OxyNEO Narcotic 2012/01/01 Oxycodone + naloxone Targin opioid 2009/12/30 Common Date Marketed in Generic Name Trade Classification Canada Name(s) (yyyy/mm/dd) Paliperidone Invega Antipsychotic agent 2007/10/02 Invega Paliperidone palmitate Antipsychotic agent 2010/07/28 Sustenna Palonosetron Aloxi 5TH3 antagonist 2012/03/14 Palonosetron + netupitant Akynzeo Antiemetic 2017/12/04 Cotazym ECS Pancrelipase 4 & Cotazym Pancreatic enzymes 2012/02/06 65B Synthetic analogue of Pasireotide Signifor 2013/11/26 somatostatin Patiromer Veltassa Potassium binder 2020/03/09 Pazopanib Votrient Antineoplastic agent 2011/08/25 Perampanel Fycompa Anticonvulsant 2013/09/04 Pertuzumab Perjeta Antineoplastic agent 2013/04/23 Phosphate Phosphate Effervescent 2017/01/01 Sandoz Pirfenidone Esbriet Anti-fibrotic agent 2013/01 Plerixafor Mozobil Hematopoietic agent 2012/01/26 Pneumococcal 13-valent Prevnar 13 Vaccine 2010/03/17 conjugate vaccine Polidocanol Varithena Sclerosing agent 2015/08/04 Polyethylene glycol 3350 Lax-a-day Laxative 2009/03/09 « first? previous ? 4 5 6 7 8 9 10 11 12 next ? last »

© 2017 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions Source URL (retrieved on 2021-10-02 19:12): http://www.dpic.org/druglisting/pomalidomide